Allocetra

Phase 2Small molecule

EEnlivex Therapeutics Ltd.

Allocetra is one of 88 small molecule programs targeting Psoriatic Arthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Psoriatic ArthritisRecruiting

OsteoarthritisActive, not recruiting

Knee OsteoarthritisRecruiting

Psoriatic ArthritisPhase 1

Recruiting

OsteoarthritisPhase 2

Active, not recruiting

Knee OsteoarthritisPhase 2

Recruiting

Competition

Competitive Landscape

141 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Toradol

Roche

Preclinical

1 2

Allocetra

EEnlivex Therapeutics Ltd.

Phase 2

1 3

Cataflam

Bayer Aspirin

Enbrel

2 6

Glucophage

EMD Serono

Preclinical

1 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 8

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Knee Osteoarthritis

NCT07580716

Clinical

Trials by Indication[1]

Osteoarthritis1 trial

Intra-articular Allocetra in Osteoarthritis of the of the Temporomandibular Joint (TMJ)

Recruiting·—·Phase 1·NCT06748651·6 enrolled

Psoriatic Arthritis1 trial

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

Recruiting·EEnlivex Therapeutics Ltd.·Phase 1·NCT06522035·6 enrolled

Osteoarthritis, Knee1 trial

A Phase 1/2a Randomized, Double-Blind Placebo-controlled Study of Intra-articular Allocetra in Knee Osteoarthritis

Completed·EEnlivex Therapeutics Ltd.·Preclinical·NCT06233474·134 enrolled

Knee Osteoarthritis1 trial

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis

Recruiting·EEnlivex Therapeutics Ltd.·Phase 2·NCT07580716·182 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Allocetra. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allocetra compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allocetra. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Enlivex Therapeutics Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEnlivex Therapeutics Ltd.

Allocetra

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Osteoarthritis1 trial

Psoriatic Arthritis1 trial

Osteoarthritis, Knee1 trial

Knee Osteoarthritis1 trial

References

Drug Info

Quick Facts

Related News